357M-1
TCL1 (MRQ-7) Mouse Monoclonal Antibody
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352203
NACRES:
NA.41
Produtos recomendados
fonte biológica
mouse
Nível de qualidade
100
500
conjugado
unconjugated
forma do anticorpo
culture supernatant
tipo de produto de anticorpo
primary antibodies
clone
MRQ-7, monoclonal
descrição
For In Vitro Diagnostic Use in Select Regions (See Chart)
Formulário
buffered aqueous solution
reatividade de espécies
human
embalagem
vial of 0.1 mL concentrate (357M-14)
vial of 0.5 mL concentrate (357M-15)
bottle of 1.0 mL predilute (357M-17)
vial of 1.0 mL concentrate (357M-16)
bottle of 7.0 mL predilute (357M-18)
fabricante/nome comercial
Cell Marque®
técnica(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
Isotipo
IgG
controle
B-cell lymphoma, tonsil
Condições de expedição
wet ice
temperatura de armazenamento
2-8°C
visualização
cytoplasmic, nuclear
Informações sobre genes
human ... TCL1A(8115)
Categorias relacionadas
Descrição geral
T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene that is involved in T-cell prolymphocytic leukemia (T-PLL). TCL1 protein is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells. TCL1 is down-regulated in the latest stage of B-cell differentiation. TCL1 is overexpressed in Burkitt lymphoma, the majority of AIDS-related non-Hodgkin lymphoma-designated immunoblastic plasmacytoid lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and primary cutaneous B-cell lymphoma. Therefore, the most useful application of anti-TCL1 is the discrimination of B-cell lymphomas from T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma.
Qualidade
 IVD |  IVD |  IVD |  RUO |
Ligação
TCL1 Positive Control Slides, Product No. 357S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
forma física
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Nota de preparo
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Outras notas
For Technical Service please contact: 800-665-7284 or email: [email protected]
Informações legais
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Não está encontrando o produto certo?
Experimente o nosso Ferramenta de seleção de produtos.
Escolha uma das versões mais recentes:
Certificados de análise (COA)
Lot/Batch Number
Não está vendo a versão correta?
Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
M G Narducci et al.
Cancer research, 60(8), 2095-2100 (2000-04-29)
Chromosomal rearrangements observed in T-cell prolymphocytic leukemia involve the translocation of one T-cell receptor gene to either chromosome 14q32 or Xq28, deregulating the expression of cellular protooncogenes of unknown function, such as TCL1 or its homologue, MTCP1. In the human
E Pescarmona et al.
Histopathology, 49(4), 343-348 (2006-09-19)
To investigate by immunohistochemical analysis the expression of the TCL1 oncogene product and of CD27 in 25 cases of primary cutaneous B-cell lymphomas (PCBCL) classified according to the World Health Organization-European Organization for Research and Treatment of Cancer classification of
J Roos et al.
Pathobiology : journal of immunopathology, molecular and cellular biology, 69(2), 59-66 (2001-12-26)
TCL1, MTCP1 and TCL1b are three members of a new family of oncogenes that are expressed in T cell leukemias of ataxia telangiectasia patients (T-PLL, T-CLL). TCL1 is located at 14q32.1 and activated by juxtaposition to the alpha/delta-locus at 14q11
Yuri Pekarsky et al.
Hematology/oncology clinics of North America, 18(4), 863-879 (2004-08-25)
Mature leukemias and lymphomas are a heterogeneous group of lymphoproliferative neoplasias characterized by the accumulation of mature lymphocytes in lymph nodes, other lymphoid tissues, and peripheral blood. In this article we discuss molecular mechanisms leading to the pathogenesis of two
Scott J Rodig et al.
The American journal of surgical pathology, 32(1), 113-122 (2007-12-29)
The distinction between Burkitt (BL) or atypical Burkitt/Burkitt-like lymphomas harboring a MYC translocation (MYC+) and diffuse large B-cell lymphomas (DLBCLs) with high proliferation fractions but without a MYC translocation (MYC-) can be difficult using standard morphologic and immunohistochemical criteria. Recently
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica